Open AccessCo‐administration phenoxodiol with doxorubicin synergistically inhibit the activity of sphingosine kinase‐1 (SphK1), a potential oncogene of osteosarcoma, to suppress osteosarcoma cell growth both in vivo and in vitro
Author(s) -
Yao Chen,
Wu Sujia,
Li Dong,
Ding Huimin,
Wang Zuyu,
Yang Yongjiang,
Yan Shichang,
Gu Zhangping
Publication year - 2012
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2012.04.002
Subject(s) - sphingosine kinase 1 , protein kinase b , cancer research , cell growth , doxorubicin , sphingosine , sphingosine kinase , biology , kinase , ceramide , apoptosis , microbiology and biotechnology , signal transduction , chemistry , sphingosine 1 phosphate , biochemistry , receptor , genetics , chemotherapy
Elucidation of the mechanisms of chemo‐resistance and implementation of strategies to overcome it will be pivotal to improve the survival for osteosarcoma (OS) patients. We here suggest that sphingosine kinase‐1 (SphK1) might be the key factor contributing to chemo‐resistance in OS. Our Western‐blots and immunohistochemistry results showed that SphK1 is over‐expressed in multiple clinical OS tissues. Over‐expression of SphK1 in OS cell line U2OS promoted its growth and endorsed its resistance against doxorubicin, while knocking‐down of SphK1 by shRNA inhibited U2OS cell growth and increased its sensitivity to doxorubicin. Co‐administration phenoxodiol with doxorubicin synergistically inhibited SphK1 activity to trigger cellular ceramide accumulation, and achieved synergistic anti‐OS growth effect, accompanied with a significant increased of apoptosis and cytotoxicity. Increased cellular level of ceramide by the co‐administration induced the association between Akt and Protein Phosphatase 1 (PP1) to dephosphorylate Akt, and to introduce a constitutively active Akt (CA‐Akt) restored Akt activation and diminished cell growth inhibition. Further, phenoxodiol and doxorubicin synergistically activated apoptosis signal‐regulating kinase 1(ASK1)/c‐jun‐NH2‐kinase (JNK) signaling, which also contributed to cell growth inhibition. Significantly, the role of SphK1 in OS cell growth and the synergistic anti‐OS effect of phenoxodiol and doxorubicin were also seen in a mice OS xenograft model. In conclusion, our data suggest that SphK1 might be a critical oncogene of OS and co‐administration phenoxodiol with doxorubicin synergistically inhibited the activity of SphK1 to suppress osteosarcoma cell growth both in vivo and in vitro.